Aaron Royston - Net Worth and Insider Trading

Aaron Royston Net Worth

The estimated net worth of Aaron Royston is at least $147 Million dollars as of 2024-11-10. Aaron Royston is the Director of Akero Therapeutics Inc and owns about 3,954,858 shares of Akero Therapeutics Inc (AKRO) stock worth over $136 Million. Aaron Royston is also the Director, 10% Owner of Ventyx Biosciences Inc and owns about 5,011,536 shares of Ventyx Biosciences Inc (VTYX) stock worth over $11 Million. Details can be seen in Aaron Royston's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Aaron Royston has not made any transactions after 2021-10-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Aaron Royston

To

Aaron Royston Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Aaron Royston owns 5 companies in total, including VYNE Therapeutics Inc (VYNE) , Akero Therapeutics Inc (AKRO) , and Elevation Oncology Inc (ELEV) among others .

Click here to see the complete history of Aaron Royston’s form 4 insider trades.

Insider Ownership Summary of Aaron Royston

Ticker Comapny Transaction Date Type of Owner
VYNE VYNE Therapeutics Inc 2019-06-25 director
AKRO Akero Therapeutics Inc 2019-06-24 director
ELEV Elevation Oncology Inc 2022-05-25 10 percent owner
LIMIT LIMIT 2021-10-25 director & 10 percent owner
LIMIT LIMIT 2023-09-14 director

Aaron Royston Latest Holdings Summary

Aaron Royston currently owns a total of 2 stocks. Among these stocks, Aaron Royston owns 3,954,858 shares of Akero Therapeutics Inc (AKRO) as of June 24, 2019, with a value of $136 Million and a weighting of 92.51%. Aaron Royston also owns 5,011,536 shares of Ventyx Biosciences Inc (VTYX) as of October 25, 2021, with a value of $11 Million and a weighting of 7.49%.

Latest Holdings of Aaron Royston

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AKRO Akero Therapeutics Inc 2019-06-24 3,954,858 34.43 136,165,761
VTYX Ventyx Biosciences Inc 2021-10-25 5,011,536 2.20 11,025,379

Holding Weightings of Aaron Royston


Aaron Royston Form 4 Trading Tracker

According to the SEC Form 4 filings, Aaron Royston has made a total of 0 transactions in Akero Therapeutics Inc (AKRO) over the past 5 years. The most-recent trade in Akero Therapeutics Inc is the acquisition of 250,000 shares on June 24, 2019, which cost Aaron Royston around $4 Million.

According to the SEC Form 4 filings, Aaron Royston has made a total of 1 transactions in Ventyx Biosciences Inc (VTYX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Ventyx Biosciences Inc is the acquisition of 312,500 shares on October 25, 2021, which cost Aaron Royston around $5 Million.

Insider Trading History of Aaron Royston

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Aaron Royston Trading Performance

GuruFocus tracks the stock performance after each of Aaron Royston's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Aaron Royston is -8.16%. GuruFocus also compares Aaron Royston's trading performance to market benchmark return within the same time period. The performance of stocks bought by Aaron Royston within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Aaron Royston's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Aaron Royston

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 13.56 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 10.82 LIMIT LIMIT LIMIT LIMIT LIMIT

Aaron Royston Ownership Network

Ownership Network List of Aaron Royston

No Data

Ownership Network Relation of Aaron Royston

Insider Network Chart

Aaron Royston Owned Company Details

What does VYNE Therapeutics Inc do?

Who are the key executives at VYNE Therapeutics Inc?

Aaron Royston is the director of VYNE Therapeutics Inc. Other key executives at VYNE Therapeutics Inc include Chief Legal Officer and GC Mutya Harsch , 10 percent owner Perceptive Life Sciences Master Fund Ltd , and Interim CFO Tyler Zeronda .

VYNE Therapeutics Inc (VYNE) Insider Trades Summary

Over the past 18 months, Aaron Royston made no insider transaction in VYNE Therapeutics Inc (VYNE). Other recent insider transactions involving VYNE Therapeutics Inc (VYNE) include a net purchase of 13,000 shares made by Patrick G Lepore ,

In summary, during the past 3 months, insiders sold 0 shares of VYNE Therapeutics Inc (VYNE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of VYNE Therapeutics Inc (VYNE) were sold and 13,000 shares were bought by its insiders, resulting in a net purchase of 13,000 shares.

VYNE Therapeutics Inc (VYNE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

VYNE Therapeutics Inc Insider Transactions

No Available Data

Aaron Royston Mailing Address

Above is the net worth, insider trading, and ownership report for Aaron Royston. You might contact Aaron Royston via mailing address: 200 Cardinal Way, 2nd Floor, Redwood City Ca 94063.